IFNG and infection: To this end, we adopted a modified version of the second infection model, wherein an IFN-γ-targeting neutralization antibody or an isotype matched control antibody was intranasally administered both on 1 day before and at 6 h after the LCMV Armstrong challenge (Figure 5C).